Answers are grounded in this paper and cite their sources.
This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification. Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: